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บทคดัยอ่ 
วตัถุประสงค์: เฟนิโตอนิเป็นยากนัชกัทีม่ปีระสทิธภิาพในการลดความเสีย่งของ
การเกดิอาการชกัหลงัสมองบาดเจบ็ในระยะแรก การศกึษาวจิยัน้ีมวีตัถุประสงค์
เพื่อศกึษาระดบัยาของเฟนิโตอนิและปจัจยัทีส่มัพนัธก์บัระดบัยาเฟนิโตอนิในการ
ควบคุมอาการชกัของผูป้่วยทีม่กีารบาดเจบ็ทีส่มอง วธิกีารศกึษา: รวบรวมขอ้มลู
ผู้ป่วยที่มกีารบาดเจบ็ของสมองที่โรงพยาบาลสรรพสทิธิประสงค์ ประเทศไทย
ในช่วงเดอืนพฤษภาคม 2555 – มกราคม 2556 จาํนวน 122 คน วดัระดบัยาเฟนิ
โตอนิในช่วงวนัที ่3-7 ของการไดร้บัยาเฟนิโตอนิ โดยผูป้่วยไดร้บัยาเฟนิโตอนิ 2 
รปูแบบคอื 100 มก. ทุก 8 ชัว่โมง หรอื 300 มก. ทุก 24 ชัว่โมง โดยอาจไดร้บัยา
ขนาดเพิม่หรอืไม่ไดร้บั เภสชักรบนัทกึขอ้มูลของผูป้่วยไดแ้ก่ อายุ เพศ น้ําหนัก 
ส่วนสูง ประวตัิความเจบ็ป่วย ประวตัิการใช้ยา การวนิิจฉัย แบบแผนการใช้ยา 
ประวตัทิางสงัคม (การสบุูหรีแ่ละการดื่มแอลกอฮอล)์ การตรวจทางหอ้งปฏบิตักิาร 
(ระดบัแอลบูมนิในเลอืด ระดบัครเีอตนีินในเลอืด AST, ALT, BUN) ในแบบบนัทกึ
ขอ้มลู วเิคราะหค์วามสมัพนัธร์ะหว่างระดบัยาในเลอืดกบัปจัจยัทีอ่าจมผีลต่อระดบั
ยาในเลอืดดว้ยสถติไิค-สแควร ์ผลการศกึษา: ในผูป้ว่ย 122 ราย ม ี64 รายทีร่ะดบั
ยาเฟนิโตอนิรวมตํ่ากว่าระดบัการรกัษา  (รอ้ยละ 52.5) และ 52 รายอยูใ่นช่วงการ
รกัษา (รอ้ยละ 42.9) และ 6 รายมรีะดบัเป็นพษิ (รอ้ยละ 4.9) ทัง้น้ี ผูป้่วย 11 ราย 
(รอ้ยละ 9.0) ไมส่ามารถควบคมุอาการอาการชกัในช่วง 7 วนัแรกของการรกัษาได ้
ในจํานวนน้ีมผีูป้่วยทีม่รีะดบัยาตํ่ากว่าระดบัการรกัษา และในระดบัรกัษาอย่างละ 
5 ราย (รอ้ยละ 45.5) และมผีูป้ว่ย 1 ราย (รอ้ยละ 9.1) ทีม่รีะดบัเป็นพษิ ภาวะไขม้ี
ความสมัพนัธก์บัระดบัยาในเลอืดอยา่งมนียัสาํคญัทางสถติ ิ(P = 0.001) สว่นระดบั
แอลบูมนิในเลอืดและความรุนแรงของการบาดเจบ็ทีส่มองไม่พบความสมัพนัธ ์(P 
> 0.05) สรุป: ผูป้่วยมากกว่ารอ้ยละ 50 ทีไ่ดร้บัยาเฟนิโตอนิในการป้องกนัอาการ
ชกัมรีะดบัยาในเลอืดตํ่ากว่าระดบัการรกัษา การปรบัขนาดยาเพือ่ใหไ้ดร้ะดบัยาใน
เลอืดอยา่งเหมาะสมจะมปีระสทิธภิาพในการควบคุมอาการชกั และไขส้มัพนัธก์บั
ระดบัยาเฟนิโตอนิในเลอืด 
คาํสาํคญั: เฟนิโตอนิ การบาดเจบ็ทีส่มอง อาการชกัหลงับาดเจบ็ทีส่มอง 
 
 
Abstract 
Objectives: Phenytoin is an effective drug used for decreasing the risk of 
early post- traumatic seizures in patients with traumatic brain injury.   This 
study investigated phenytoin serum concentrations and select factors related 
to seizure control in patients with traumatic brain injury.  Methods:  Data of 
122 patients with traumatic brain injury were collected from 
Sumprasithiprasong Hospital, Thailand between May 2012 and January 
2013.  Phenytoin serum concentrations were collected on day 3 -  7 after 
starting phenytoin.  Two regimens of phenytoin were employed; 100 mg q 8 
hr or 300 mg q 24 hr with or without a loading dose.  The data of patients 
such as age, gender, weight, height, illness history, medical history, 
diagnosis, dosage regimen, social history ( smoking and alcohol drinking) , 
blood chemistry laboratory ( serum albumin, serum creatinine, AST, ALT, 
BUN)  were  recorded by a research pharmacist in the data collection form. 
Chi-square test was used to test the association between phenytoin 
concentration levels and select factors. Results:  Of the 122 patients, total 
phenytoin concentrations were in sub- therapeutic range in 64 patients 
( 52. 5% ) , therapeutic range for 52 patients ( 42. 6% )  and toxic range in six 
patients (4.9%). Eleven patients (9.0%) failed to achieve control of seizures 
during the first 7 days. Of these 11 patients, 5 of them (45.5%) had phenytoin 
concentrations in sub- therapeutic level, while another 5 ( 45. 5% )  were in 
therapeutic range, and one patient ( 9. 1% )  was in toxic level.  Fever was 
correlated with phenytoin concentration (P = 0.001); while hypoalbuminemia 
and severity of brain injury were not (P > 0.05). Conclusion: More than half 
of the patients receiving phenytoin prophylactically had phenytoin sub-
therapeutic level.   Phenytoin dosage should be adjusted appropriately to 
effectively control seizures. Fever was associated with phenytoin level.  
Keywords: phenytoin, traumatic brain injury, posttraumatic seizure  
 
Introduction 
    Traumatic brain injury (TBI) is associated with high risk of 
seizures.  Penetrating injury or subdural hematoma is a 
common cause with a short latency between the injury and 
the onset of epileptic seizures.1,2 Post-traumatic epilepsy (> 7 
days after TBI)  is reported in 2 -  5% of closed head injuries 
but up to 50%  or more after penetrating head injury.3 Early 
post- traumatic seizures ( 7 days after TBI) represent about 
2 - 5% of all causes of epilepsy.4,5 These early seizures, which 
appear in the first week after the TBI, are related to the 
severity of the injury.  They do not have a clearly defined 
mechanism, but they are a risk factor for development of post-
traumatic epilepsy ( PTE) .  PTE appears in 5%  of all the 
patients suffering from all TBI, and in 15 - 20% of the patients 
suffering from a severe TBI.5  
Phenytoin ( PHT) , phenobarbital, and carbamazepine 
( CBZ)  are efficacious for TBI related epilepsy.6 Phenytoin is 
the most frequently used AED. Young et al (1979) described 
the effectiveness of phenytoin for prophylaxis of post-
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traumatic epilepsy with the dose that maintained serum 
concentrations between 10 and 20 mg/ L.7 Only 6%  of these 
patients experienced seizures during the first year after injury 
( first week excluded) .  However, only one- third of these 
patients are known to have continued to take phenytoin after 
the first month, and only half of these had serum phenytoin 
concentrations above the desired minimal level.  A study in 
Czechoslovakia showed that both of phenytoin ( 160 -  240 
mg/d) and phenobarbital (30 - 60 mg/d) administered orally 
prevented post- traumatic seizures.8 The incidence of post-
traumatic epilepsy was 25%  in the control and 2. 1%  in the 
prophylactically treated group.  Moreover, the efficacy of 
prophylactic pharmacotherapy has been proven in long- term 
studies lasting 8 to 13 years. On the other hand, Young et al 
reported failure of prevention of post- traumatic epilepsy by 
phenytoin.9,10 Population pharmacokinetics of phenytoin in 
head injury Thai patients within 7 days after trauma and 
factors related to phenytoin pharmacokinetics parameters 
have been studied in the last three years.11 The objective of 
our study was to investigate phenytoin serum concentrations 
and other factors related to the efficacy of phenytoin in early 
seizure control in patients with traumatic brain injury in the 7-
days post-trauma period.  
   
Materials and Methods 
 
Data from one hundred twenty-two patients with traumatic 
brain injury data were collected from Sumprasithiprasong 
Hospital, Thailand between May 2012 and January 2013.11 
Each patient received a regimen of phenytoin sodium 
(Dilantin®). Phenytoin serum concentrations were collected on 
days 3 - 7 after starting the drug. Two regimens of phenytoin 
had been prescribed; 100 mg q 8 hr or 300 mg q 24 hr IV with 
or without a loading dose by IV infusion. Three serum samples 
were collected from each patient during days 3 - 7 according 
to a table of random numbers, one sample in the distribution 
phase, and two samples in the elimination phase. Sampling 
times for all patients during the distribution phase were at 1, 
1.5, 2, and 2.5 hours after dosing. Sampling times in the 
elimination phase were during hours 3 - 8 after dosing for the 
group receiving 100 mg every 8 hours, and hours 3 - 24 after 
dosing for the group receiving 300 mg every 24 hours. The 
average total phenytoin concentrations were categorized into 
three groups: subtherapeutic level (< 10 mg/L), therapeutic 
range (10 - 20 mg/L) and toxic level (> 20 mg/L).  
To be included in the study the patients had to be 
diagnosed with early traumatic brain injury and took phenytoin 
by IV infusion in the first 7 days. They also had to be 18 years 
or older. Those with the following were excluded: having liver 
or renal disease, being pregnant, having had severe adverse 
drug reactions such as Stevens-Johnson Syndrome (SJS) or 
Drug Reaction with Eosinophilia and Systemic Symptoms 
(DRESS) syndrome, or taking other antiepileptic drugs.   
Phenytoin serum concentrations were measured by 
COBAS INTERGRA 400 Plus (Roche, Switzerland) with % CV 
within run (n = 80) of 2.2%, a sensitivity of 0.42 μg/ml, and 
linearity of 0.42 - 40 μg/ml. The data of patients such as age, 
gender, weight, height, illness history, medical history, 
diagnosis, dosage regimen, social history (smoking and 
alcohol drinking), blood chemistry laboratory (serum albumin, 
serum creatinine, AST, ALT, BUN) were  recorded by a 
research pharmacist in the data record form.  Fever was 
defined as body temperature of more than 38.5C, for more 
than 3 days during the 7 days after TBI. Hypoalbuminemia 
was defined as the albumin level in the blood of less than 3 
g/dL. AST or ALT more than 3 times the normal value was 
defined as an abnormal level. BUN more than 80 g/dL and 
serum creatinine more than 2 g/dL were defined as an 
abnormal level. Severity of head injury was categorized based 
on the Glasgow Coma Scale; mild (13 – 15), moderate (9 - 
12), and severe (3 – 8).  
  
Statistical analysis 
Data were presented as descriptive statistics including 
frequency with percentage and mean with standard deviation. 
Chi-square test was used to examine the association between 
phenytoin serum concentrations (3 categories) and relating 
factors including fever, hypoalbuminemia, and severity of head 
injury. Statistical significance for all tests was set at the level 
of P < 0.05.  
  
Results and Discussions 
 
Of the 122 patients with TBI included, they were with an 
average age of 35.3 years and the majority was male (85.2%). 
Most of them had a severe head injury (83.6%) (Table 1). 
Hypoalbuminemia was found in 17.2%.   
 
 
ไทยเภสชัศาสตรแ์ละวทิยาการสขุภาพ ปี 11 ฉบับ 3, กค. – กย. 2559 89 Thai Pharm Health Sci J Vol. 11 No. 3, Jul. – Sep. 2016 
 Table 1   Characteristics of patients with traumatic brain 
injury using phenytoin (N = 122).  
Characteristics  Mean ± SD 
Age (y) 35.3±16.70 
Height (cm) 163.9±7.81 
ABW (kg) 58.6±9.13 
IBW (kg) 60.7±7.57 
Gender 
    Male 
 
104 (85.2) 
Severity of head injury  
Mild  
Moderate  
Severe  
 
3 (2.5) 
17 (13.9) 
102 (83.6) 
Hypoalbuminemia (< 3 g/dL)  21 (17.2) 
Smoking  38 (31.1) 
Alcohol use  28 (23.0) 
Underlining disease  
DM  
Hypertension 
Epilepsy 
Hyperlipidemia 
Others  
15 (12.3) 
6 (4.9) 
4 (3.3) 
3 (2.5) 
3 (2.5) 
5 (4.0) 
   (arthritis, gout, asthma, SLE, heart disease)  
 
The average dose of phenytoin was 5.25  0.81 mg/kg/d. 
Most of the patients with TBI received a loading dose of 
phenytoin (86.9%) and took a phenytoin maintenance dose of 
100 mg q 8 hr (68.0%) (Table 2).   
 
 Table 2  Dosage regimen of phenytoin for patients with 
traumatic brain injury (N = 122).  
Dosage regimen  Number (%)      
Mean dosage (mg/kg/day)  5.25 ± 0.81 
Continuous Regimen  
100 mg q 8 hr 
 300 mg q 24 hr 
 
83 (68.0) 
39 (32.0) 
Loading dose 
 - None  
 - First dose only  
500 mg  
750 mg  
850 mg  
1000 mg 
- Multiple dose (started with 750 mg)  
16 (13.1) 
106 (86.9) 
1 (0.8) 
93 (76.2) 
1 (0.8) 
4 (3.3) 
7 (5.7) 
 
Eleven of the 122 patients (9.0%) experienced seizure 
during the first seven days.  Of these 11 patients, an equal 
number of them had phenytoin concentrations in the sub-
therapeutic and therapeutic ranges (five patients each or 45.5% 
each). One of the 11 patients (9.1%) had a phenytoin 
concentration at the toxic level. Once phenytoin 
concentrations were considered, these 11 patients included 
five of 64 patients with sub-therapeutic level (7.8%), five of 52 
patients with therapeutic level (9.6%), and one of six patients 
(16.7%) with toxic phenytoin level (Table 3). 
Of the 122 patients with TBI, the majority was with a sub-
therapeutic level of total phenytoin concentrations (64 patients 
or 52.5%), followed by those with levels in therapeutic range 
(52 patients or 42.6%). Only six patients (4.9%) had phenytoin 
levels at the toxic level (Table 3).   
 
 Table 3  Correlation of phenytoin serum level and seizure 
control (N = 122).  
Phenytoin level (mg/L) Number  
(%) 
Number of patients with seizure 
in early phase (%) 
Subtherapeutic (<10)  64 (52.5) 5 (7.8) 
Therapeutic (10 – 20)  52 (42.6) 5 (9.6) 
Toxic (> 20)  6 (4.9) 1 (16.7) 
Total 122 (100.0) 11 (100.0) 
 
Among various factors, having a fever was correlated with 
phenytoin concentration (P = 0.001); while serum albumin 
level and severity of brain injury were not (P > 0.05) (Table 4).  
 
 Table 4  Factors influencing phenytoin level in the early 
phase (N = 122).  
Factors P-value* 
Fever  0.001 
Hypoalbuminemia  0.412 
Severity of brain injury  0.321 
* Chi-square test, with a significance level set at P < 0.05.  
 
Thirty percent of patients with cranio- cerebral trauma 
develop one or more seizures followed by post- traumatic 
epilepsy (PTE) in a great number of cases. Phenytoin is an 
antiepileptic drug recommended for prevention of post-
traumatic seizure, but its efficacy in the early or late phase of 
trauma is debatable. Young et al ( 1979) investigated the 
efficacy of phenytoin to prevent seizure after head injury in the 
first year.7 Eighty- four patients received an intravenous 
phenytoin dose of 11 mg/kg body weight immediately after an 
intramuscular dose of 13 mg/ kg body weight.  This was 
followed by daily intramuscular maintenance doses, usually 
8. 8 mg/ kg body weight, until oral medication could be 
tolerated. Six percent of patients experienced seizures during 
the first year after injury. One-third of these patients continued 
to receive phenytoin after the first month only.  Half of them 
had serum phenytoin concentrations above the desired 
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minimal level.  The incidence of post- traumatic seizures in 
these patients was greatly reduced despite the low rate of 
long- term drug compliance.  Therefore, phenytoin therapy in 
the early phase of TBI may be efficacious for prevention of 
late seizures.  
In a study, Czechoslovakia patients with TBI received low 
doses of phenytoin (160 - 240 mg/d) and phenobarbital (30 - 
60 mg/ d)  by oral administration.8 The incidence of PTE was 
25%  in the control group and 2. 1%  in the prophylactically 
treated group.  Only one patient ( 0. 7% )  developed seizures 
during the course of the prophylactic treatment.  Thus, the 
efficacy of prophylactic phenytoin has been demonstrated, 
although not sufficiently recognized. 
A randomized-  double- blind placebo- controlled study 
showed failure of phenytoin to prevent post-traumatic seizures 
especially in the first week after severe head trauma.9 Over 
78% of the phenytoin treated patients had serum 
concentrations of at least 10 micrograms/ml at 1, 3, and 7 
days after injury.  There was no significant difference in the 
percentage of patients having early seizures in the treated and 
placebo groups (P = 0.99). There was no significant difference 
in the interval from injury to first seizure between the treated 
and placebo groups ( P =  0. 41) .  The early administration of 
phenytoin did not decrease the occurrence of seizures in the 
1st week after head injury.  
As shown in our study the effectiveness of phenytoin to 
control post- traumatic seizure was not correlated with 
phenytoin serum concentration.  Factors that may determine 
control of seizures include the severity of head injury with 
major risk factors being a penetrating head wound, 
hematoma, depressed skull fracture and low serum albumin 
that affects total serum phenytoin.  Nevertheless, phenytoin 
level should be monitored and the dosage regimen adjusted 
to remain in the therapeutic range.  If some patients do not 
achieve control despite therapeutic serum concentrations, a 
second drug should be added. Fever could be associated with 
a decreased phenytoin serum level. A prospective study found 
that the effect of fever correlated with antiepileptic drug levels 
serum concentrations in 14 boys in a pediatric chronic care 
facility. Blood samples and 24-hour urine collections were 
obtained during febrile illness (temperature greater than 101 
degrees F for more than 24 hours). Phenytoin level decreased 
by more than 40% from pre-illness baseline. Phenytoin 
binding protein and phenytoin absorption were not altered. 
The cause of a decrease in phenytoin level was the induction 
of the hepatic oxidative enzyme system.12  
Early seizures after the traumatic brain injury become a 
risk factor for the development of PTE. 5  Predictors of PTE 
were post- traumatic amnesia longer than 24 hours in 90. 6% 
of patients, neurological deficit in 86. 45% , impressive skull 
fracture with rupture of dura in 81. 3%  and intracranial 
haemorrhage in 40.6%.4 Eighteen percent of the 38 patients 
experienced one or more late seizures (i.e., seizures occurring 
8 or more days post-trauma) by the time of the 1-year follow-
up.13 In a randomized double- blind placebo- controlled study 
Young et al demonstrated the failure of prophylactically 
administered phenytoin for late post- traumatic seizures.10  
One- hundred- seventy- nine patients were followed for 18 
months to detect the occurrence of seizures and to serially 
measure plasma phenytoin concentrations.  There was no 
significant difference between the percentage of patients 
having late seizures in the treated and placebo groups ( P = 
0. 75) .  The time between injury and seizures did not 
significantly differ between the two groups.  The results 
provided no support for the continued use of phenytoin in the 
low therapeutic range for prophylaxis against late post-
traumatic seizures.  However, higher phenytoin plasma 
concentrations and higher compliance rates may decrease the 
occurrence of late PTE, because no patient with a phenytoin 
plasma concentration of 12 microgram/ ml or higher had a 
seizure.  
Phenytoin and carbamazepine prevent early seizures, but 
neither of these nor did phenobarbital influence the 
development of late PTE.14 The efficacy of classic antiepileptic 
drugs ( phenobarbital, phenytoin, carbama-zepine, valproate 
acid)  as a prophylactic treatment for PTE has not been 
confirmed.  From an experimental perspective, drugs such as 
lipid peroxidation inhibitors, neuroprotectors ( especially 
antioxidants) , glutamate receptor blockers, and drugs that 
modulate apoptosis via caspase inhibition show promise. The 
recommended therapeutic strategy is not to administrate 
AEDs indiscriminately, but to analyze risk factors and design 
a careful preventive strategy for late seizures employing AEDs 
with proven efficacy in partial seizures and with the best 
achievable tolerability.5 The proportion of cases that 
developed seizures was 0 -  10%  in patients that received 
treatment compared to 2 - 50% in those who were untreated.  
In a Cochrane systematic review of 890 patients from 10 
RCTs assessing PHT or CBZ, the pooled relative risk (RR) for 
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prevention of early seizures was 0.33 (95% CI of 0.21 - 0.52). 
By contrast, the RR for prevention of late seizures was 1. 28 
( 95%  CI of 0. 90- 1. 81) .  Mortality and neurological disability 
were similar in the two treatment groups. The use of PHT was 
associated with a non- significant increased risk of skin rash. 
In addition, cognitive performance was significantly affected 
by PHT in severely injured patients at one month. Treatment 
withdrawal was followed by improvement in cognitive 
function.6 Levetiracetam was as effective as phenytoin in 
preventing early post- traumatic seizures, but patients 
receiving levetiracetam had a higher incidence of abnormal 
EEG findings (P = 0.003).15  
 
Conclusion 
 
In our study more than half of patients with traumatic brain 
injury who received phenytoin prophylactically for early 
seizures had sub-therapeutic phenytoin concentrations. Fever 
may decrease phenytoin serum concentration. None of the 
other variables were correlated with phenytoin serum 
concentrations.  Phenytoin dosage and serum levels should 
be adjusted appropriately to control seizures for patients with 
early traumatic brain injury.  
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